As from the last eras number of the revolution in the drug delivery technologies have been seen to attain the targeted drug delivery or site specific action of the drug. The prospects of the drug delivery by using biomimetic nanoparticles such as virosomes is an motivating research & development field as showing targeted action by fusion with the targeted action by fusion through target cell. It can be engaged as vehicle & vaccines furthermore victory of virosomal drug delivery depends on the method used to make the encapsulated bioactive materials, characterization & formulation of finished products. They are reconstituted viral envelopes that can be conveyance of different macromolecules as these are biocompatible, biodegradable, nonautoimmunogenic. Virosomes denotes such a unique system for presentation of antigen to immune system. Peptides, nucliecacid & medications such as antitoxins, anticancer agents &steroids can be encapsulated. This review focus on various aspects of Virosomes, such as Structure of Virosomes Component, Advantages, disadvantages, Method of preparation, Characterization, recent Patents and applications of Virosomes etc.
INTRODUCTION
One of the causes of stoppage of the promising drug during development is failure to deliver to the target cell, tissue & organ 1, 2 . The novel therapeutics includes the delivery that targets the drug to the particular cell & tissue by controlled release & receptor mediated uptake 3 . Furthermore the new generation of the therapeutics especially against cancer or neurogenerative disorders desires delivery system which target the drug to the host cell & tissue 4 .Virosomal technology is developed in order to overcome the difficulty of incomplete delivery to the targetting cell, tissue & organs of the body 5 .virosomes have become talentedcandidate for the targetting the drug & antigen delivery 6 . As novel drug delivery technology should deliver improved bioavailability & should reduce the dose of the drug, during the clinical test several drugs fails due to the lack of delivery technology. The prospect of drug delivery & targetting using virosomes is an interesting field of research & development 7 . Virosomal technology grants a novel sophisticated delivery system to meet the challenges of targeting to the cell & tissues; these are lipoidal biocarrier for site specific targetting 8 Sendai virus virosomes generated by reconstitution of Sendai fusion protein 9,10. In short Virosomes are regenerate empty influenza virus envelopes where infectious nucleocapside be substituted by compound of choice as they having pure fusion activity thus deliver the incorporated compounds to or inside the target cells, in this compounds like drug, antigen, genes can be incorporated. One of major advantage which is the object of great interest of using virosomes as guards the incorporated compounds from proteolytic degradation & low pH within the endosomes as permits their content to remain intact while it reaches to the cytoplasm. Furthermore achievement of virosomal drug delivery depends on the technique used to prepare the encapsulated bioactive materials, characterisation & formulation of finished products. As virosomes are biodegradable, biocompatible, nontoxic & nonautoimmunogenic attempts were made to use them as a vaccines or adjuvants as well as delivery system for drug, nucleic acid, gene for therapeutic application 11 .
I) STRUCTURE OF VIROSOMES
Virosomes are semi-synthetic sphere-shaped or unilamellar complex derived from nucleic acid free viral particles, bilayer 13 . NA present on IRIV's exterior aids the action by the same mechanism through which it enhances influenza virus pathogenicity it catalyses the breakdown of Nacetylneuraminic acid from bound sugar residue leads to decrease viscosity of host's mucus permitting to the influenza virus an easier entree to epithelial cells, the same procedure leads to demolition of HA receptors within cell membrane to which viruses & IRIV's binds. This allows virus particle to avoid aggregation as newly formed virus particle do not adhere to infected host cell membrane after budding. The mode of action of IRIV's is dependent on the influenza haemagglutinin which is intercalated into the phospholipidbilayer &steadies the liposomes bases by preventing fusion with other liposomes. HA is major influenza antigen which is formed from two polypeptides HA1& HA2 which are involved in receptor binding & membrane fusion. HA1-Globular head contain a receptor site that has a high affinity for sialic acid present on antigen presenting cell (APC's) surface like lymphocytes & macrophages.
HA2-The fusion of IRIV's with endosomal membrane is then mediated by HA2 polypeptide 14 .  Site specific delivery to various organs: cytotoxic agents.
 Potential for sustained release dosage formsdexamethasone palmitate, barbiturates, physostigmine salicylate 15 .
III) ADVANTAGES OF VIROSOMES
 This technology is approved by FDA for use in human & has proven to have safety profile.
 Completely biodegradable, Biocompatible & nontoxic.
 No risk of disease transmission, no auto immunogenicity.
 Enables delivery of drug to conveyance into cytoplasm of target cell.
 Defends drug against degradation.
 Promotes combination movement in the endolysosomal pathway.
 Controlled by either injection or nasally.
 Allows tolerant specific modular vaccine regimes.
 Up scaling according to standard procedure possible.  Appropriate for elderly &infants 16 .
IV) DISADVANTAGES OF VIROSOMES
 They might induce immune responses since they often have viral glycoprotein on the surface.
 Rapid disintegration in the blood compartment is potential issue connected with virosomes,  Short shelf life.
 Manufacturing problems.
 Poor quality of raw materials.
 Pay load is too slow.
 Non availability of data related to chronic use of virosomes.
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 Rapid disintegration can be overcome by growing the stability of virosomes or making virosomes reaches targetting sites inside a short time after administration 16 .
 Use of high quality products with improved purification protocols.
 Quality control assay can be made by using sophisticated instruments & batch to batch variability can be checked.
 Use of remote loading techniques to overcome payload problems.
 Improvement in shelf life using appropriate cryoprotectants & lyoprotectants.
 Scale up problems can be enhanced by selection of proper method of preparation & sterilization by autoclaving or membrane filtration coupled with aseptic & validated pyrogen removal Lal test.
 By selecting drugs with narrow therapeutic index 17, 18 . 
V) METHOD OF PREPARATION OF VIROSOMES

2.
Fusion activity-Generally virosomes displays pH dependent film combination movement like local flu infection similar to native influenza virus, Fluorescent resonance energy transfer assay is used to visualized the virosomal fusion with artificial & biological target membrane fusion can be assessed in vitro with excimer virosomal combination with organic or counterfeit target film can be surveyed in vitro to measure utilizing pyrene-named lipid where decrease of surface density of pyrene-Phosphatidylcholine label on fusion with unlabelled membrane leads to decrease in fluorescence.
3.
Structure & size-Negative-stain electron microscopy generally used to determine ultrastructure and size of virosomes. The staining solution is of neutral pH, to avoid acid-induced conformational changes of HA. 
VII) MECHANISM OF ACTION OF VIROSOMES
IX) EVALUATION OF VIROSOMES
 Protein detection-Relatively uniform protein to lipid ratio is observed in prepared virosomes. To confirm the presence of HA protein, Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) method is used.
 Surface charge-Free flow electrophoresis.
 Structure & size-Negative stain electron microscopy with neutral staining agents is used, determined by photo correlation spectroscopy, transmission electron microscopy, dynamic light scattering, and gel permeation & gel exclusion techniques.
 Lamellarity-It can be determined 13p-NMR, Freeze fracture electron microscopy.
 Percent free drugs-It can be determined by mini column centrifugation, gel exclusion, radiolabel ling, protamine aggregation.
 Phase behaviour-Differential scanning colorimetry, freeze fracture electron microscopy.
 Drug release-Diffusion cell dialysis
 Animal toxicity-It can be determined by monitoring history, pathology & survival rates.
 Pyrogenicity-It can be determined by Rabbit fever test, Limulus ambeocyte lysate (LAL) test.
 Surface chemical analysis-Static secondary ion mass spectrometry.
X) PHARMACOKINETIC OF VIROSOMES
Information regarding differences in the pharmacological effect of free drug & encapsulated drug can be given by the pharmacokinetic studies that help in dose designing; it can give the information regarding the absorption, distribution & degradation time course of retention, dissemination & debasement of the virosomal transport in-vivo. Effect of pharmacokinetic parameter on virosomes shown following outcomes- Greater therapeutic index.
 Greater concentration at targeted sites.

Protection of drug in plasma.
 Decrease in toxicity& nonspecific reaction.
 Reduction in nonspecific localization. 20 . 
XI) APPLICATIONS OF VIROSOMES
